Bluebird strikes a CAR-T deal with ViroMed; Ex-Allergan president takes over Chase Pharma;

@FierceBiotech: Q&A: Philips on what's next after the first year of HealthTech. More from FierceMedicalDevices | Follow @FierceBiotech

@JohnCFierce: This week we've been seeing the venture cash flowing. Bodes well for lots more action in 2016. | Follow @JohnCFierce

> Moving on from a scaled-back partnership with Celgene ($CELG), bluebird bio ($BLUE) signed a deal with ViroMed to develop CAR-T therapies for cancer, paying $1 million up front and promising up to $48 million per resulting product. News

> Former Allergan ($AGN) President Douglas Ingram has taken on the CEO role at Chase Pharmaceuticals, a privately held company developing treatments for neurological disorders include Alzheimer's disease. More

> KaloBios ($KBIO), the near-death biotech scooped up by Martin Shkreli, has fleshed out its management ranks with some leaders from Shkreli's privately held Turing Pharmaceuticals. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Syneron Medical bogged down with slumping sales for ultrasound fat-zapping device. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate. Story | Follow @VarunSaxena2

@EmilyWFierce: Check out this week's Dx Digest, featuring liquid biopsy news from Guardant Health and Circulogene Theranostics. Report | Follow @EmilyWFierce

> Novartis weighs sale of contact lens business as Alcon unit struggles to chart growth. More

> U.K.'s NHS funds 1,000+ patient trial of a minimally invasive artificial lung. Story

Pharma News

@FiercePharma: Flu expert warns against USDA move to build bird flu vaccine stockpile. Article | Follow @FiercePharma

@CarlyHFierce: @RepCummings to Shkreli: "To claim that a 50% discount after a 5,000% increase is a 'price cut' is Orwellian double-speak." | Follow @CarlyHFierce

> Japan poised to put 70% price lid on biosimilars, cap generics at 50% of reference drug. Story

> Struggling Eisai looks for help in China with new generics deal. More

CRO News

> Medidata reaches into South Korea with a CRO partnership. News

> Parexel revamps its trial management system for drugmakers large and small. Report

> INC's financiers bank another $272M in the IPO afterglow. More

> Survey: CRO employee turnover soars amid an industry boom. Story

> Quotient Clinical snapped up by Gillings-founded buyout firm. Article

Pharma Manufacturing News

> Wockhardt says U.K. regulatory agency issued GMP certificate to troubled Chikalthana plant. News

> EU agency gives Baxalta green light to begin manufacturing two plasma-based therapies. Story

> Radiopharmaceutical manufacturer Iason Italia hit with noncompliance report. Article

> FDA cites two Endo subsidiaries for product recalls. Report

> Danaher acquires German quality inspection firm Laetus for undisclosed price. Item

Pharma Asia News

> India's GVK Bio gets infusion of cash from ChrysCapital. Item

> Generic drugs face April 2016 price caps in Japan. More

> Ascletis gets $20M from Goldman in race to China HCV approval. Report

> Singapore researchers close in on 'liquid biopsy' to track cancer progress, treatment. Story

> BMJ: Drugmakers get quid pro quo for participation in Indian health camps. Article

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.